

SEASON

A Solution to the GLP-1 Cost Crisis



The problem

Americans are increasingly seeking glucagon-like peptide 1 (GLP-1) receptor agonist drugs for weight loss and diabetes management, leading to a sharp increase in prescriptions over the past few years and unprecedented impacts:

2,082%

increase in prescriptions since 2019¹

\$10,000

per member, per year²

2/3 weight re-gain

after stopping weight loss medication³

Lifestyle management interventions coupled with thoughtful prescription programs are the key to sustained behavior change and outcomes.⁴ **Season Health** is the industry leading food-as-medicine platform designed to drive sustained weight loss in concert with members' GLP-1 plan. We do this through our practice of **registered dietitians and a curated food marketplace** via value-based programs. Our programs are fully at risk against clinical and engagement outcomes and key cost of care indicators, so that **employers and health plans can deliver exceptional care while managing costs.**

Our offerings to support GLP-1 programs



When considering a GLP-1

Season provides a lifestyle program that can prevent the need for a GLP-1, or if a GLP-1 is deemed medically necessary, Season educates and prepares members for their prescription.



During use of GLP-1

For members who have been using a GLP-1, Season provides a lifestyle program to complement the prescription, assist with medication management, and help the member build healthy habits for long-term success.



Off-ramp from GLP-1

For members who have been using a GLP-1 and are looking to cease use, Season provides an off-ramp into a lifestyle program for sustained results, preventing the "yo-yo" effect and future GLP-1 prescription.



partnerships@seasonhealth.com



seasonhealth.com

SEASON

The Season Health approach

An **individually tailored nutrition prescription** and access to Season's platform with **over 200,000 recipes** along with medically-tailored meals and groceries.


One-on-one medical nutrition therapy provided by a dedicated registered dietitian to promote sustainable lifestyle and behavior change.

A dedicated **peer support group** and on-demand nutrition and culinary **education**.

Access to Season's **Benefits Bank**, with integration of existing payer and government benefits.

Regular reassessment of the patient's condition, biomarkers, and needs.

Stepping down to a **maintenance phase**, with continued access to Season's platform and resources to support long term change and sustained outcomes.



"I wouldn't know where to start without Season. Thank you - I couldn't do it without your help."

- a Season member using GLP-1, navigating medication management

Season's outcomes

In a recent study, Season members demonstrated the following clinical improvements and behaviors.

-2.32%

Avg. 90 day BMI reduction
(starting BMI > 28)

-1.34

Avg. 90 day A1c reduction
(starting A1c ≥ 8)

90%+

of members are engaged
at 6 months

Season provides value

Season works flexibly with health plan customers to design the optimal business model for these programs. Dependent on plan, Season estimates a 3:1 return on investment in year one of these programs.

Interested in learning more about partnering with Season on weight management for your member population?

Contact: partnerships@seasonhealth.com

References

1. Khan TK. Prescriptions for Trendy Diabetes and Weight-Loss Drugs Increased Over 2,000% Since 2019. Komodo Health, Inc. February 17, 2023. Accessed August 29, 2023 from <https://www.komodohealth.com/insights/prescriptions-for-trendy-diabetes-and-weight-loss-drugs-increased-over-2000-since-2019>
2. Ally AJ, Bell DB, Craff M, Garbe J, Gruenhaupt M, Heinen P, Russo EM. Payer strategies for GLP-1 medications for weight loss: Helping payers understand the landscape, develop a coverage strategy, and minimize waste. Milliman, Inc. August 2023. Accessed August 29, 2023 from https://us.milliman.com/-/media/milliman/pdfs/2023-articles/8-28-23_glp-1s-for-weight-loss_20230824.ashx
3. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. *Diabetes Obes Metab.* 2022;24(8):1553-1564. doi:10.1111/dom.14725
4. Spreckley M, Seidell J, Halberstadt J. Perspectives into the experience of successful, substantial long-term weight-loss maintenance: a systematic review. *Int J Qual Stud Health Well-being.* 2021;16(1):1862481. doi:10.1080/17482631.2020.1862481